

CITATION REPORT

List of articles citing

2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation

DOI: 10.1016/j.cjca.2014.08.001

Canadian Journal of Cardiology, 2014, 30, 1114-30.

Source: <https://exaly.com/paper-pdf/57700526/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
353	Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1541-6	3.8	22
352	Applying the atrial fibrillation guidelines update to manage your patients with atrial fibrillation. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1241-4	3.8	2
351	Is low body weight a novel risk factor for thromboembolic events in patients with non-valvular atrial fibrillation?. <i>Circulation Journal</i> , 2015 , 79, 960-1	2.9	2
350	Validation of Risk Scoring System Excluding Female Sex From CHA2DS2-VASc in Japanese Patients With Nonvalvular Atrial Fibrillation [Subanalysis of the J-RHYTHM Registry. <i>Circulation Journal</i> , 2015 , 79, 1719-26	2.9	30
349	New Modified CHA2DS2-VA Scoring System for Japanese Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2015 , 79, 1682-4	2.9	1
348	Performance of the "CCS Algorithm" in real world patients. 2015 , 7, 18-21		
347	Amiodarone use is associated with increased risk of stroke in patients with nonvalvular atrial fibrillation: a nationwide population-based cohort study. 2015 , 94, e849		7
346	The Impact of Novel Anticoagulants: Should All AF Patients Now Be Anticoagulated?. 2015 , 66, 530-9		1
345	Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc \geq 1, or higher?. 2015 , 113, 1165-9		40
344	Epidemiology, diagnosis, and management of atrial fibrillation in women. 2015 , 7, 605-14		23
343	'Realworld' use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry. 2015 , 113, 1159-61		16
342	Monitoring and management of patients with chronic atrial fibrillation: Is there added value in the identification of clinical phenotypes?. 2015 , 14, 382-3		
341	The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 1207-18	3.8	36
340	Atrial Fibrillation: Would You Prefer a Pill or 150 Joules?. 2015 , 66, 655-7		2
339	Subclinical atrial fibrillation and stroke: insights from continuous monitoring by implanted cardiac electronic devices. <i>Europace</i> , 2015 , 17 Suppl 2, ii40-6	3.9	12
338	Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. 2015 , 36, 653-6		41
337	The new Canadian Cardiovascular Society algorithm for antithrombotic therapy of atrial fibrillation is appropriately based on current epidemiologic data. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 20-3	3.8	7

336	Canadian Cardiovascular Society 2014 algorithm for anticoagulation therapy in atrial fibrillation debated. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 1-2	3.8	3
335	Catheter ablation for asymptomatic atrial fibrillation?. 2015 , 13, 243-8		1
334	Device-detected atrial fibrillation: what to do with asymptomatic patients?. 2015 , 65, 281-94		43
333	Anticoagulation therapy: Perioperative anticoagulation-are we at 'a bridge too far'?. 2015 , 12, 133-4		9
332	Managing atrial fibrillation. 2015 , 65, 532-9		15
331	Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. 2015 , 46, 936-41		123
330	Inguinal hernia. 2015 , 187, 602-603		
329	The case against using hypertension as the only criterion for oral anticoagulation in atrial fibrillation. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 576-9	3.8	4
328	Risk Factors of Ischemic Stroke and Subsequent Outcome in Patients Receiving Hemodialysis. 2015 , 46, 2477-81		41
327	Temporal trends and sex differences in pulmonary vein isolation for patients with atrial fibrillation. 2015 , 12, 1979-86		37
326	Patients with atrial fibrillation and CHA2DS2-VASc score 1: "To anticoagulate or not to anticoagulate? That is the question!". 2015 , 12, 2515-20		4
325	Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. 2015 , 36, 1805-11		293
324	The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: A systemic review and meta-analysis. 2015 , 195, 237-42		22
323	Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation. 2015 , 13, 341-53		7
322	[Pre-interventional, peri-interventional and post-interventional anticoagulation in the setting of catheter ablation for atrial fibrillation : current practice and practical approach]. 2015 , 40, 45-9		1
321	Implications for your practice: Important changes in the 2014 guideline for the management of patients with atrial fibrillation. 2015 , 127, 535-8		2
320	Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease. 2015 , 24, 183-92		20
319	Drugs acting on the heart: anti-arrhythmics. 2015 , 16, 232-236		

318	Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. 2015 , 37, 2506-2514.e4		106
317	Stroke Risk Stratification in Patients With Atrial Fibrillation: Comme Ci, Comme B, Plus B Change. 2015 , 66, 1860-3		6
316	New oral anticoagulants. 2015 , 187, 603		
315	Canadian Stroke Best Practice Recommendations: secondary prevention of stroke guidelines, update 2014. 2015 , 10, 282-91		79
314	Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation. 2015 , 17, 61		11
313	The Long-Term Use of Warfarin Among Atrial Fibrillation Patients Discharged From an Emergency Department With a Warfarin Prescription. 2015 , 66, 347-354.e2		27
312	Stroke Risk Factors Beyond the CHA ₂ DS ₂ -VASc Score: Can We Improve Our Identification of "High Stroke Risk" Patients With Atrial Fibrillation?. 2015 , 116, 1781-8		47
311	Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. 2015 , 4, e002322		60
310	Mobitz II. 2015 , 187, 603		
309	High-intensity interval training improves cardiovascular health, exercise capacity, and quality of life in permanent atrial fibrillation: a case study. 2015 , 40, 1321-3		1
308	The Disconnect Between Novel Oral Anticoagulant Eligibility and Provincial Drug Coverage: An Albertan Anticoagulation Clinic Audit. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 1047-50	3.8	4
307	Safety of urgent cardioversion for patients with recent-onset atrial fibrillation and flutter. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 239-41	3.8	7
306	Stroke risk reduction with oral anticoagulation using CHA ₂ DS ₂ -VASc in a Japanese AF population: A modeling analysis. 2015 , 181, 247-54		5
305	Atrial fibrillation patients categorized as "not for anticoagulation" according to the 2014 Canadian Cardiovascular Society algorithm are not "low risk". <i>Canadian Journal of Cardiology</i> , 2015 , 31, 24-8	3.8	13
304	Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation. 2016 , 12, 443-449		
303	Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility. 2016 , 9, 309-16		1
302	Appropriateness of Apixaban Dosing to Prevent Stroke in Patients with Atrial Fibrillation: A Pilot Study. 2016 , 69, 449-453		4
301	Guideline-recommended therapy, including beta-blocker utilization, in patients with chronic heart failure: results from a Canadian community hospital heart function clinic. 2016 , 69		

300	Individualising Anticoagulant Therapy in Atrial Fibrillation Patients. <i>Arrhythmia and Electrophysiology Review</i> , 2016 , 5, 102-9	3.2	4
299	Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. 2016 , 116, S33-S40		7
298	CHADS2 score has a better predictive value than CHA2DS2-VASc score in elderly patients with atrial fibrillation. 2016 , 11, 941-6		5
297	Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention. 2016 , 9, 337-347		12
296	Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis. 2016 , 69, 409-414		4
295	Which components of the CHA2DS2-VASc score are the most important in obstructive sleep apnea patients with atrial fibrillation?. 2016 , 27, 347-51		2
294	Wound haematoma following defibrillator implantation: incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial. <i>Europace</i> , 2017 , 19, 1002-1006	3.9	13
293	Anticoagulation and population risk of stroke and death in incident atrial fibrillation: a population-based cohort study. 2016 , 4, E1-6		5
292	Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. 2016 , 3, e000441		27
291	Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial. 2016 , 11, 159		10
290	2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. 2016 , 115, 893-952		76
289	Electrophysiological abnormalities in subjects with lone atrial fibrillation - Too little, too late?. 2016 , 16, 149-151		
288	Anticoagulantes orales directos para el tratamiento de los pacientes con fibrilaci3n auricular no valvular. 2016 , 23, 82-88		1
287	Crioabla3n con bal3n en fibrilaci3n auricular. 2016 , 23, 138-142		
286	Tratamiento farmacol3gico de la fibrilaci3n auricular. Antiarr3tmicos y anticoagulantes orales. 2016 , 16, 33-39		
285	Trials and tribulations: Antiarrhythmic drugs for the acute conversion of atrial fibrillation. 2016 , 13, 1784-5		1
284	Is It Time to Systematically Replace Warfarin With a New Oral Anticoagulant for Higher-Risk Patients With Nonvalvular Atrial Fibrillation?. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1203.e9-1203.e17	3.8	2
283	CHADS-VASc Recalibration With an Additional Age Category (50-64 Years) Enhances Stroke Risk Stratification in Chinese Patients With Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1381-1387	3.8	14

282	Stroke prevention for patients with atrial fibrillation: values and preferences of Canadian emergency medicine trainees. 2016 , 34, 1685-7		6
281	Net Clinical Benefit of Dabigatran Over Warfarin in Patients With Atrial Fibrillation Stratified by CHADS-VASc and Time in Therapeutic Range. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1247.e15-1247.e21	3.8	12
280	Insertable cardiac monitors in the diagnosis of syncope and the detection of atrial fibrillation: A systematic review and meta-analysis. 2016 , 23, 1261-72		17
279	Evidence-Based Anticoagulation Decision Making for Atrial Fibrillation--How We Are Doing? (Maybe Not So Well?). <i>Canadian Journal of Cardiology</i> , 2016 , 32, 278-80	3.8	2
278	Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. 2016 , 118, 1409-24		76
277	Is 10-second electrocardiogram recording enough for accurately estimating heart rate in atrial fibrillation. 2016 , 215, 175-8		4
276	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1170-1185	3.8	212
275	At What Age Does Stroke Risk Increase in Patients With Atrial Fibrillation? Does It Depend on Where You Live?. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1364-1365	3.8	1
274	Perioperative Management of the Direct Oral Anticoagulants: A Case-Based Review. 2016 , 30, 1073-84		12
273	Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants. 2016 , 11, 950-967		2
272	Rate Control in Atrial Fibrillation. <i>Contemporary Cardiology</i> , 2016 , 67-77	0.1	
271	Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy. 2016 , 180, 82-9		17
270	Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke. 2016 , 47, 2380-5		29
269	The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. 2016 , 82, 285-300		28
268	Cardiology residents' anticoagulation preferences for stroke prophylaxis in atrial fibrillation patients. 2016 , 223, 63-64		
267	How to estimate heart rate from pulse rate reported by oscillometric method in atrial fibrillation: The value of pulse rate variation. 2016 , 222, 1022-1026		4
266	Rate control in atrial fibrillation. 2016 , 388, 818-28		88
265	A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. 2016 , 181, 92-100		17

264	Underutilization of Ambulatory ECG Monitoring After Stroke and Transient Ischemic Attack: Missed Opportunities for Atrial Fibrillation Detection. 2016 , 47, 1982-9		34
263	Rivaroxaban in Chronic Hemodialysis Patients. 2016 , 43, 227-8		6
262	Prevençi3 farmacol3gica de embolia por fibrilaci3 auricular y sus escalas de riesgo de embolia y sangrado. 2016 , 23, 65-72		1
261	Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con. 2016 , 11, 2085-2092		17
260	Short-Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90'000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient Care. 2016 , 5,		15
259	Diagnosis and management of supraventricular tachycardias. 2016 , 188, E466-E473		8
258	Dabigatran use in elderly patients with atrial fibrillation. 2016 , 115, 152-60		78
257	A multi-hospital analysis of predictors of oral anticoagulation prescriptions for patients with actionable atrial fibrillation who attend the emergency department. 2016 , 18, 71-78		3
256	Presence of diabetic microvascular complications does not incrementally increase risk of ischemic stroke in diabetic patients with atrial fibrillation: A nationwide cohort study. 2016 , 95, e3992		5
255	Left atrial appendage closure versus oral anticoagulation for preventing stroke in people with atrial fibrillation. 2016 ,		78
254	Management of postoperative atrial fibrillation after cardiac surgery. 2016 , 31, 183-90		13
253	Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1108-16	3.8	6
252	Anticoagulation in Elderly Patients With Chronic Kidney Disease: How Safe Is It?. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 941.e3-5	3.8	
251	Effect of a Multidisciplinary Approach for the Management of Patients With Atrial Fibrillation in the Emergency Department on Hospital Admission Rate and Length of Stay. 2016 , 118, 64-71		14
250	Learning to Make Decisions: Are Medical Postgraduate Trainees Getting With the Atrial Fibrillation Guidelines?. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 714-6	3.8	
249	Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1355.e9-1355.e14	3.8	15
248	Catheter Ablation as First-Line Therapy for Atrial Fibrillation: Ready for Prime-Time?. 2016 , 18, 71		4
247	Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1247.e23-1247.e28	3.8	16

246	Temporal Patterns and Predictors of Rate vs Rhythm Control in Patients Attending a Multidisciplinary Atrial Fibrillation Clinic. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1247.e7-1247.e13	3.8	
245	Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. 2016 , 30, 201-14		15
244	Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 747-53	3.8	72
243	Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 986.e17-22	3.8	17
242	Atrial Flutter and Fibrillation in the Emergency Setting. 2016 , 61-87		
241	Individualized approaches to thromboprophylaxis in atrial fibrillation. 2016 , 173, 143-58		9
240	Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 824-8	3.8	9
239	Ablation of Complex Fractionated Atrial Electrograms for Atrial Fibrillation Rhythm Control: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 791-802	3.8	8
238	Guidelines for Potassium Channel Blocker Use. 2016 , 8, 495-501		1
237	Emerging Tools for Stroke Prevention in Atrial Fibrillation. 2016 , 4, 26-39		9
236	Asymptomatic atrial fibrillation burden and thromboembolic events: piecing evidence together. 2016 , 14, 761-9		5
235	Prior bleeding, future bleeding and stroke risk with oral anticoagulation in atrial fibrillation: What new lessons can ARISTOTLE teach us?. 2016 , 175, 168-71		1
234	Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry. 2016 , 212, 311-7		6
233	Predictors for Progression of Atrial Fibrillation in Patients Awaiting Atrial Fibrillation Ablation. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1348-1354	3.8	17
232	Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?. 2016 , 16, 183-200		52
231	Integrating Frailty Assessment Into Cardiovascular Decision Making. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 139-41	3.8	7
230	Atrial fibrillation management: evaluating rate vs rhythm control. 2016 , 14, 713-24		3
229	Appropriate Use of Antithrombotic Medication in Canadian Patients With Nonvalvular Atrial Fibrillation. 2016 , 117, 1107-11		13

228	Atrial Fibrillation and Stroke: Making Sense of Recent Observations on Anticoagulation. 2016 , 34, 317-28		5
227	The atrial fibrillation conundrum in dialysis patients. 2016 , 174, 111-9		20
226	Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. 2016 , 16, 171-82		2
225	The Arrhythmic Patient in the Emergency Department. 2016 ,		
224	A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. 2016 , 203, 785-90		1
223	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2016 , 13, e136-221		58
222	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2016 , 67, e27-e115		246
221	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i> , 2016 , 133, e506-74	16.7	142
220	The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 336-43	3.8	11
219	The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 169-76	3.8	86
218	Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: Which scoring system should be used for Asians?. 2016 , 13, 46-53		53
217	A Decision Analysis of Percutaneous Left Atrial Appendage Occlusion Relative to Novel and Traditional Oral Anticoagulation for Stroke Prevention in Patients with New-Onset Atrial Fibrillation. 2016 , 36, 366-74		14
216	Outcomes for Emergency Department Patients With Recent-Onset Atrial Fibrillation and Flutter Treated in Canadian Hospitals. 2017 , 69, 562-571.e2		41
215	Rational Medical Therapy Is the Key to Effective Cardiovascular Disease Prevention. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 626-634	3.8	2
214	Factors Associated With Cardiac Electrophysiologist Assessment and Catheter Ablation Procedures in Patients With Atrial Fibrillation. 2017 , 3, 302-309		2
213	Orthostatic Symptoms of Transient Ischemic Attack - Revised. <i>Canadian Journal of Emergency Medicine</i> , 2017 , 19, 163-165	0.6	1
212	The gap between indicated and prescribed stroke prevention therapies in a high-risk geriatric population. 2017 , 48, 261-266		5
211	Treatment of atrial fibrillation with warfarin among older adults with end stage renal disease. 2017 , 30, 831-839		5

210	Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 737-746	3.8	39
209	Anticoagulation for atrial fibrillation in dialysis patients: What is known and what does the future hold?. 2017 , 14, 652-653		
208	The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. 2017 , 69, 777-785		193
207	Clinical implications of reversal agents for direct oral anticoagulants. 2017 , 13, 153-159		7
206	Cardioembolic Stroke. 2017 , 120, 514-526		153
205	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. 2017 , 103, 307-314		163
204	The anticoagulation choices of internal medicine residents for stroke prevention in non-valvular atrial fibrillation. 2017 , 93, 308-312		6
203	The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015. 2017 , 35, e12254		17
202	Decision-making interventions to stop the global atrial fibrillation-related stroke tsunami. 2017 , 12, 222-228		12
201	Unnecessary overuse. Study of [h]advisable practices [f]or patients with atrial fibrillation. 2017 , 217, 181-187		
200	Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. <i>Circulation</i> , 2017 , 135, 1851-1867	16.7	302
199	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. 2017 , 189, 137-145		170
198	How do family medicine residents choose an anticoagulation regimen for patients with nonvalvular atrial fibrillation?. 2017 , 18, 472-481		6
197	Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study. 2017 , 40, 835-840		7
196	Indications and appropriate selection of novel oral anticoagulants in patients with atrial fibrillation. 2017 , 103, 1129-1137		6
195	Atrial fibrillation with a structurally normal heart in pregnancy: An international survey on current practice. 2017 , 10, 74-78		5
194	Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 965-976	3.8	68
193	New-Onset Atrial Fibrillation in the Critically Ill. 2017 , 45, 790-797		81

192	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. 2017 , 69, 1363-1371		84
191	2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack. 2017 , 12, 302-320		52
190	Characterization of Guideline Evidence for Off-label Medication Use in the Intensive Care Unit. 2017 , 51, 529-542		2
189	Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. 2017 , 34, 357-377		10
188	Comparison of health-related quality of life in patients with atrial fibrillation treated with catheter ablation or antiarrhythmic drug therapy: a systematic review and meta-analysis protocol. <i>BMJ Open</i> , 2017 , 7, e017577	3	4
187	Prognostic factors of clinical endpoints in elderly patients with atrial fibrillation during a 2-year follow-up in China: An observational cohort study. 2017 , 96, e7679		3
186	Rate Control With Beta-blockers Versus Calcium Channel Blockers in the Emergency Setting: Predictors of Medication Class Choice and Associated Hospitalization. 2017 , 24, 1334-1348		3
185	Active Supraventricular Arrhythmias. 2017 , 83-163		
184	Cardiovascular Conditions in the Observation Unit: Beyond Chest Pain. 2017 , 35, 549-569		0
183	Unnecessary overuse. Study of "inadvisable practices" for patients with atrial fibrillation. 2017 , 217, 181-187		0
182	Efficacy of adjunctive measures used to assist pulmonary vein isolation for atrial fibrillation: a systematic review. 2017 , 32, 58-68		3
181	Association of Atrial Fibrillation and Oral Anticoagulant Use With Perioperative Outcomes After Major Noncardiac Surgery. 2017 , 6,		5
180	Warfarin Use in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review of Stroke and Bleeding Outcomes. 2017 , 4, 2054358117735532		8
179	Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. 2017 , 11, 243-256		20
178	Meta-analysis of ATRIA versus CHADS-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. 2017 , 227, 436-442		19
177	Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 37-41	6.4	22
176	Cardiac monitoring for detection of atrial fibrillation after TIA: A systematic review and meta-analysis. 2017 , 12, 33-45		18
175	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardıaca y Electrofisiologıa (SOLAECE). <i>Europace</i> , 2017 , 19, 1588-1623	3.9	135

174	Aversion to ambiguity and willingness to take risks affect therapeutic decisions in managing atrial fibrillation for stroke prevention: results of a pilot study in family physicians. 2017 , 11, 1533-1539		5
173	Stroke Prevention for Patients with Atrial Fibrillation: Beyond the Guidelines. <i>Journal of Atrial Fibrillation</i> , 2017 , 9, 1475	0.8	16
172	Clinical Stroke prevention in atrial fibrillation. 2017 , 47, 13-23		2
171	Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF): study protocol for a randomised controlled trial. 2018 , 19, 117		5
170	Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. 2018 , 34, 1945-1957		2
169	Introduction. 2018 , 1-6		
168	Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program. 2018 , 131, 945-955.e3		21
167	What Surgeons Should Know About Non-Vitamin K Oral Anticoagulants: A Review. 2018 , 153, 577-585		21
166	Covert atrial fibrillation and atrial high-rate episodes as a potential cause of embolic strokes of undetermined source: Their detection and possible management strategy. 2018 , 72, 1-9		15
165	CAEP Acute Atrial Fibrillation/Flutter Best Practices Checklist. <i>Canadian Journal of Emergency Medicine</i> , 2018 , 20, 334-342	0.6	22
164	Emergency medicine considerations in atrial fibrillation. 2018 , 36, 1070-1078		10
163	Use of Direct Oral Anticoagulants in Canadian Primary Care Practice 2010-2015: A Cohort Study From the Canadian Primary Care Sentinel Surveillance Network. 2018 , 7,		13
162	Elevated Incidence of Atrial Fibrillation and Stroke in Patients With Atrial Flutter-A Population-Based Study. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 774-783	3.8	8
161	The winding path towards rationale anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation. 2018 , 39, 474-476		2
160	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 214-233	3.8	125
159	Clinical Trials for Atrial Fibrillation—What Do We Know?. 2018 , 630-642		
158	Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. 2018 , 33, 1683-1689		17
157	Non-Vitamin K-Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With CKD: Pragmatic Considerations for the Clinician. 2018 , 72, 717-727		10

156	Optimizing primary care management of atrial fibrillation: The rationale and methods of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) study. 2018 , 201, 149-157			16
155	Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. <i>BMJ Open</i> , 2018 , 8, e018180	3		31
154	Between- and within-site variation in medication choices and adverse events during procedural sedation for electrical cardioversion of atrial fibrillation and flutter. <i>Canadian Journal of Emergency Medicine</i> , 2018 , 20, 370-376	0.6		0
153	Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. 2018 , 283, 282-292			16
152	Atrial fibrillation occurring transiently with stress. 2018 , 33, 58-65			18
151	Acute Management of Atrial Fibrillation: From Emergency Department to Cardiac Care Unit. 2018 , 36, 141-159			7
150	Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA DS VASc 1 or 2): A treatment dilemma. 2018 , 36, e12310			1
149	Prevention of Stroke in Atrial Fibrillation. 2018 , 1092-1100			
148	Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants. 2018 , 34, 285-295			7
147	Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. 2018 , 49, 98-106			67
146	Predictors of obtaining follow-up care in the province of Ontario, Canada, following a new diagnosis of atrial fibrillation, heart failure, and hypertension in the emergency department. <i>Canadian Journal of Emergency Medicine</i> , 2018 , 20, 377-391	0.6		8
145	What is the Impact of Frailty on Prescription of Anticoagulation in Elderly Patients with Atrial Fibrillation? A Systematic Review and Meta-Analysis. <i>Journal of Atrial Fibrillation</i> , 2018 , 10, 1870	0.8		43
144	Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion. 2018 , 7, e010854			4
143	Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk. 2018 , 41, 1395-1402			13
142	Effects of a reminder to initiate oral anticoagulation in patients with atrial fibrillation/atrial flutter discharged from the emergency department: REMINDER study. <i>Canadian Journal of Emergency Medicine</i> , 2018 , 20, 841-849	0.6		3
141	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1371-1392	3.8		144
140	The Guideline-Policy Gap in Direct-Acting Oral Anticoagulants Usage in Atrial Fibrillation: Evidence, Practice, and Public Policy Considerations. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1412-1425	3.8		7
139	Left atrial appendage isolation in atrial fibrillation catheter ablation: A meta-analysis. 2018 , 34, 478-484			4

138	A randomized clinical trial of early invasive intervention for atrial fibrillation (EARLY-AF) - methods and rationale. 2018 , 206, 94-104		13
137	Diagnostic accuracy and yield of screening tests for atrial fibrillation in the family practice setting: a multicentre cohort study. 2018 , 6, E308-E315		20
136	Current and Future Use of Insertable 'Cardiac' Monitors. 2018 , 4, 1383-1396		27
135	Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke. 2018 , 19, 1597-1602		11
134	Role of the anticoagulant monitoring service in 2018: beyond warfarin. 2018 , 2018, 348-352		9
133	Differences in Heart Rate Response and Recovery After 6-Minute Walk Test Between Patients With Atrial Fibrillation and in Sinus Rhythm. 2018 , 122, 592-596		3
132	Thromboprophylaxis for Patients with High-risk Atrial Fibrillation and Flutter Discharged from the Emergency Department. 2018 , 19, 346-360		9
131	Measuring Success in Ablation of Atrial Fibrillation: Time for a Paradigm Shift?. 2018 , 11, e006582		4
130	Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management. 2018 , 19, 4		5
129	Atrial Fibrillation and Heart Failure: Untangling a Modern Gordian Knot. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1437-1448	3.8	11
128	Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. 2018 , 154, 1121-1201502		
127	A clinical decision instrument to predict 30-day death and cardiovascular hospitalizations after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) study. 2018 , 203, 85-92		6
126	Beta-blocker therapy reduces mortality in patients with coronary artery disease treated with percutaneous revascularization: a meta-analysis of adjusted results. 2018 , 19, 337-343		7
125	Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis. <i>PLoS ONE</i> , 2018 , 13, e0197583	3.7	44
124	Application of net reclassification index to non-nested and point-based risk prediction models: a review. 2019 , 40, 1880-1887		15
123	Stroke Prevention in Atrial Fibrillation: The Role of Oral Anticoagulation. 2019 , 103, 847-862		5
122	Safe Cardioversion for Patients With Acute-Onset Atrial Fibrillation and Flutter: Practical Concerns and Considerations. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 1296-1300	3.8	9
121	2017 Guidelines for the management of heart failure by pharmacists. <i>Canadian Pharmacists Journal</i> , 2019 , 152, 301-316	1.3	0

120	Antiplatelet, anticoagulant or both? A tool for pharmacists. <i>Canadian Pharmacists Journal</i> , 2019 , 152, 291-300	1.3	2
119	The Canadian Cardiovascular Society 2018 guideline update for atrial fibrillation - A different perspective. <i>Canadian Journal of Emergency Medicine</i> , 2019 , 21, 572-575	0.6	7
118	Empirical Insights When Defining the Population Burden of Atrial Fibrillation and Oral Anticoagulation Utilization Using Administrative Data. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 1412-1415	3.8	4
117	Periprocedural Anticoagulation for Cardioversion of Acute Onset Atrial Fibrillation and Flutter: Evidence Base for Current Guidelines. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 1301-1310	3.8	12
116	Catheter ablation: an ongoing revolution. 2019 , 11, S212-S215		3
115	Evaluation of the effect of prior antiarrhythmic drug use on the success of atrial fibrillation catheter ablation. 2019 , 44, 708-714		1
114	Stroke Prophylaxis for Atrial Fibrillation? To Prescribe or Not to Prescribe-A Qualitative Study on the Decisionmaking Process of Emergency Department Providers. 2019 , 74, 759-771		6
113	Atrial fibrillation and stroke: a practical guide. 2019 , 19, 208-224		13
112	Guideline Implications of Prothrombotic State Assessment in Low-Risk Atrial Fibrillation Patients: Consistency With CHADS-VASc and Support for CHADS-65. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 547-549	3.8	
111	Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. 2019 , 34, 923-933		13
110	Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants - A systematic review. <i>PLoS ONE</i> , 2019 , 14, e0213379	3.7	10
109	Rivaroxaban e malattia renale cronica: evidenze dal presente e prospettive future. 2019 , 31, 30-36		
108	Improved enantioselectivity of BioH in kinetic resolution of methyl (-)-3-cyclohexene-1-carboxylate by combinatorial modulation of steric and aromatic interactions. 2019 , 83, 1263-1269		8
107	Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 160-168	3.8	3
106	Use of modified intention-to-treat analysis in studies of direct oral anticoagulants and risk of selection bias: a systematic review. 2019 , 24, 63-69		0
105	Prescribing of oral anticoagulants in the emergency department and subsequent long-term use by older adults with atrial fibrillation. 2019 , 191, E1345-E1354		9
104	The Risk of Stroke and Stroke Type in Patients With Atrial Fibrillation and Chronic Kidney Disease. 2019 , 6, 2054358119892372		3
103	The Effect of Cardiac Rehabilitation and a Specialized Clinic on Outcomes of Patients With Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 382-388	3.8	3

102	How do aging and comorbidities impact risk of ischemic stroke in patients with atrial fibrillation. 2019 , 29, 386-391		1
101	Atrial fibrillation detected initially during acute medical illness: A systematic review. 2019 , 8, 130-141		22
100	Wearable and implantable diagnostic monitors in early assessment of atrial tachyarrhythmia burden. <i>Europace</i> , 2019 , 21, 377-382	3.9	6
99	The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. 2019 , 73, e13285		7
98	Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. 2019 , 74, 309-318		11
97	The Canadian Community Utilization of Stroke Prevention Study in Atrial Fibrillation in the Emergency Department (C-CUSP ED). 2019 , 73, 382-392		8
96	Rate Control Management of Atrial Fibrillation With Rapid Ventricular Response in the Emergency Department. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 509-517	3.8	2
95	Female sex and stroke in atrial fibrillation: an intriguing relationship. 2020 , 15, 175-179		2
94	Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Patients With Chronic Kidney Disease and Atrial Fibrillation. 2020 , 125, 210-214		21
93	Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. 2020 , 43, 216-221		4
92	Atrial fibrillation and stroke: how much atrial fibrillation is enough to cause a stroke?. 2020 , 33, 17-23		4
91	Cardiac Electronic Devices: Future Directions and Challenges. 2020 , 13, 325-338		7
90	Comorbidity burden in patients undergoing left atrial appendage closure. 2020 ,		1
89	Left Atrial Appendage Occlusion: Past, Present and Future. 2020 , 120, 1484-1491		6
88	The Canadian Cardiovascular Society Atrial Fibrillation Guidelines Program: A Look Back Over the Last 10 Years and a Look Forward. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 1839-1842	3.8	4
87	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 1847-1948 ^{3,8}		82
86	Coronary CTA to Investigate Predictive Value of Left Atrial Appendage for Cardiogenic Stroke in Patients with Nonvalvular Atrial Fibrillation. 2020 , 2020, 7351876		0
85	Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study. 2020 , 8, E877-E886		0

84	Quality of Life and Health Care Utilization in the CIRCA-DOSE Study. 2020 , 6, 935-944		13
83	Shared decision making for thromboembolic prophylaxis in non-valvular atrial fibrillation: promise and problems with the American College of Cardiology's AnticoagEvaluatoR (based on SPARCTool). 2020 , 25, 90-96		
82	The Symptom Experience of Patients With Atrial Fibrillation Before Their Initial Diagnosis. 2020 , 35, 347-357		4
81	Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation. 2020 , 16, 199-205		2
80	Rhythm versus rate control strategies regarding anticoagulant use in elderly non-valvular atrial fibrillation patients: Subanalysis of the ANAFIE (All Nippon AF In the Elderly) Registry. 2020 , 76, 87-93		4
79	Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. 2020 , 395, 339-349		23
78	Major Adverse Cardiovascular Events Associated With Postoperative Atrial Fibrillation After Noncardiac Surgery: A Systematic Review and Meta-Analysis. 2020 , 13, e007437		10
77	Benefits and Risks of Anticoagulation in Dialysis Patients With Nonvalvular Atrial Fibrillation: Navigating Through Darkness. 2020 , 75, 286-288		1
76	Etiologic Workup in Cases of Cryptogenic Stroke: A Systematic Review of International Clinical Practice Guidelines. 2020 , 51, 1419-1427		13
75	Temporal Trends in Population Rates of Incident Atrial Fibrillation and Atrial Flutter Hospitalizations, Stroke Risk, and Mortality Show Decline in Hospitalizations. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 310-318	3.8	0
74	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58'634 patients across four randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f40-f49	6.4	5
73	Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis. 2021 , 87, 2589-2601		1
72	Pathophysiology of atrial fibrillation and chronic kidney disease. 2021 , 117, 1046-1059		15
71	Anticoagulation for newly diagnosed atrial fibrillation and 90-day rates of stroke and bleeding. <i>Canadian Journal of Emergency Medicine</i> , 2021 , 23, 325-329	0.6	0
70	Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry. 2021 , 53, 485-494		
69	A randomized, controlled comparison of electrical versus pharmacological cardioversion for emergency department patients with acute atrial flutter. <i>Canadian Journal of Emergency Medicine</i> , 2021 , 23, 314-324	0.6	1
68	Assessment of individual risk of food interactions while taking warfarin. 2021 , 93, 187-192		1
67	Incidence and recurrence of new-onset atrial fibrillation detected during hospitalization for non-cardiac surgery: a systematic review and meta-analysis. 2021 , 68, 1045-1056		2

66	Thromboembolic events following cardioversion of acute atrial fibrillation and flutter: a systematic review and meta-analysis. <i>Canadian Journal of Emergency Medicine</i> , 2021 , 23, 500-511	0.6	0
65	Usage Patterns of Web-Based Stroke Calculators in Clinical Decision Support: Retrospective Analysis (Preprint).		
64	Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease. 2021 , 57,		
63	A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design. 2021 , 234, 90-100		8
62	Effect of Perindopril on Atrial Fibrillation Recurrence and Burden: Results of the Canadian Trial of Atrial Fibrillation (CTAF)-2. 2021 , 3, 1100-1107		0
61	Management of Atrial Fibrillation in 2021: An Updated Comparison of the Current CCS/CHRS, ESC, and AHA/ACC/HRS Guidelines. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 1607-1618	3.8	9
60	Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study. 2021 , 203, 121-130		2
59	Neurologists' attitudes and options for anticoagulation therapy in central China. 2021 , 75, e14305		0
58	A meta-analysis of clinical risk factors for stroke in anticoagulant-naïve patients with atrial fibrillation. <i>Europace</i> , 2021 , 23, 1528-1538	3.9	6
57	Sex Differences in Outcomes Following Left Atrial Appendage Closure. 2021 , 96, 1845-1860		2
56	Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery: A Randomized Clinical Trial. 2021 , 4, e2121867		5
55	Usage Patterns of Web-Based Stroke Calculators in Clinical Decision Support: Retrospective Analysis. 2021 , 9, e28266		1
54	Atrial Fibrillation in Patients with Chronic Kidney Disease. 2021 , 39, 435-446		1
53	2021 CAEP Acute Atrial Fibrillation/Flutter Best Practices Checklist. <i>Canadian Journal of Emergency Medicine</i> , 2021 , 23, 604-610	0.6	7
52	Long-term oral anticoagulant after catheter ablation for atrial fibrillation. <i>Europace</i> , 2021 , 23, 1157-1165.	3.9	3
51	Rhythm and rate control of atrial fibrillation in the emergency department - A large community-based observational study. <i>Canadian Journal of Emergency Medicine</i> , 2018 , 20, 834-840	0.6	4
50	Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What's New in the Literature. <i>Cardiology in Review</i> , 2021 , 29, 120-130	3.2	2
49	Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. <i>BMJ, The</i> , 2018 , 361, k1717	5.9	15

48	Current Understanding of the Role of Frailty in Cardiovascular Disease. <i>Circulation Journal</i> , 2020 , 84, 1903-1908	2.9	6
47	Sex differences in management and outcomes of patients with atrial fibrillation in the Middle East: Gulf survey of atrial fibrillation events (Gulf SAFE). <i>PLoS ONE</i> , 2017 , 12, e0175405	3.7	6
46	Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal. <i>European Cardiology Review</i> , 2016 , 11, 118-122	3.9	2
45	Anticoagulant Therapy for Atrial Fibrillation in Real Practice: Problems and Prospects. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019 , 74, 98-107	0.4	2
44	The Interactions of Nintedanib and Oral Anticoagulants-Molecular Mechanisms and Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	5
43	Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation. <i>Journal of Atrial Fibrillation</i> , 2016 , 9, 1478	0.8	14
42	Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation. <i>World Journal of Transplantation</i> , 2019 , 9, 134-144	2.3	10
41	Outcomes of digoxin vs. beta-blocker in AF: report from ESC-EHRA EORP-AF Long-Term General Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	0
40	Do we always need anticoagulation before cardioversion of atrial fibrillation in ladies?. <i>Anatolian Journal of Cardiology</i> , 2015 , 15, 602-4	0.8	
39	Stroke prevention in atrial fibrillation patients with a single stroke risk factor: Clinical decision-making and guideline recommendations: A case report and comparative analysis of the European Society of Cardiology (ESC) and American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guidelines on the management of atrial		
38	Efficacy and Limitations of Warfarin and Novel Oral Anticoagulants with Atrial Fibrillation. <i>Contemporary Cardiology</i> , 2016 , 17-36	0.1	
37	Current clinical practice guidelines in atrial fibrillation: a review. <i>Medwave</i> , 2016 , 16, e6365	2.5	4
36	Reply to the comment: With regard to the implementation of the AGREE instrument in Atrial Fibrillation Clinical Guidelines. <i>Medwave</i> , 2016 , 16, e6381	2.5	
35	Cardiovascular Pharmacotherapies Focus: Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?. <i>European Cardiology Review</i> , 2016 , 11, 115-117	3.9	3
34	Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants. <i>Healthcare Policy</i> , 2017 , 13, 68-78	1.1	2
33	OBSOLETE: Clinical Trials for Atrial Fibrillation - What do we know?. 2018 ,		
32	Comparison of the Efficacy and Safety of Warfarin and Antiplatelet Therapy in Patients with Atrial Fibrillation and End-Stage Renal Disease. <i>Korean Journal of Medicine</i> , 2019 , 94, 191-199	0.5	
31	Sequential approach for the detection of atrial fibrillation in patients with cryptogenic stroke. <i>REC: CardioClinics</i> , 2019 , 54, 224-230	0.2	1

30	Aproximaci3n secuencial en pacientes con ictus criptog3nico: un paso adelante en la organizaci3n de un proceso. <i>REC: CardioClinics</i> , 2019 , 54, 213-215	0.2	
29	Anticoagulation in Cardiac Patients. 2020 , 77-102		
28	Thoracoscopic surgical ablation versus catheter ablation as first-line treatment for long-standing persistent atrial fibrillation: the CASA-AF RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021 , 8, 1-122	1.7	1
27	The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 18,	4.6	0
26	Class I Antiarrhythmic Drugs: Na ⁺ Channel Blockers. 2020 , 31-105		0
25	Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry.. <i>Europace</i> , 2021 ,	3.9	0
24	Residual Stroke Risk in Atrial Fibrillation. <i>Arrhythmia and Electrophysiology Review</i> , 2021 , 10, 147-153	3.2	1
23	Response. <i>Canadian Family Physician</i> , 2015 , 61, 24-5	0.9	
22	Which Factors Influence Resident Physicians to Prescribe NOACs to Patients with Non-Valvular Atrial Fibrillation?. <i>Journal of Atrial Fibrillation</i> , 2016 , 9, 1462	0.8	3
21	The Atrial Fibrillation Therapies after ER visit: Outpatient Care for Patients with Acute AF - The AFTER3 Study. <i>Journal of Atrial Fibrillation</i> , 2015 , 7, 1187	0.8	6
20	Left Atrial Appendage Closure Device With Delivery System: A Health Technology Assessment. <i>Ontario Health Technology Assessment Series</i> , 2017 , 17, 1-106	3.1	1
19	Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation?. <i>Journal of Geriatric Cardiology</i> , 2018 , 15, 229-234	1.7	1
18	[Pneumonectomy for Non-small Cell Lung Cancer: Predictors of Operative Mortality and Survival]. <i>Chinese Journal of Lung Cancer</i> , 2020 , 23, 573-581	0.6	
17	Efficacy and Safety of Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation Undergoing Elective Surgical Procedures: A Meta-analysis. <i>Clinical Medicine and Research</i> , 2021 , 19, 19-25 ^{1.4}		
16	The 2020 CCS atrial fibrillation guidelines for pharmacists: Top 10 takeaways.. <i>Canadian Pharmacists Journal</i> , 2022 , 155, 107-118	1.3	1
15	Efficacy and Safety of Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation Undergoing Elective Surgical Procedures: A Meta-analysis. <i>Clinical Medicine and Research</i> , 2021 , 19, 19-25 ^{1.4}		1
14	Transient Ischemic Attack. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2022 , 157-169		
13	Validation of the CHA2DS2-VA Score (Excluding Female Sex) in Nonvalvular Atrial Fibrillation Patients: A Nationwide Population-Based Study.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	2

12	Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients with Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial.. <i>Circulation</i> , 2022 ,	16.7	5
11	Left Atrial Appendage Occlusion-A Choice or a Last Resort? How to Approach the Patient.. <i>Interventional Cardiology Clinics</i> , 2022 , 11, 135-142	1.4	
10	Association of direct oral anticoagulant-proton pump inhibitor cotherapy with adverse outcomes: protocol for a population-based cohort study. <i>BMJ Open</i> , 2022 , 12, e057991	3	
9	Direct Oral Anticoagulants vs. Warfarin in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 9,	5.4	○
8	Can I Send This Patient With Atrial Fibrillation Home From the Emergency Department?. 2022 ,		○
7	What is the Best Agent for Rate Control of Atrial Fibrillation With Rapid Ventricular Response?. 2022 ,		○
6	Remote Monitoring of Cardiac Implantable Electronic Devices: What is the Evidence?.		○
5	Left Atrial Appendage Occlusion A Choice or a Last Resort? How to Approach the Patient. 2023 , 15, 133-140		○
4	Direct oral anticoagulants for atrial fibrillation in early postoperative valve repair or bioprosthetic replacement. 2023 ,		○
3	Family Physician Prescribing Practices and Perspectives on Shared Decision-Making Regarding the Use of Oral Anticoagulants for Stroke Prevention in Patients 75 Years or Older With Atrial Fibrillation. 2023 , 14, 215013192311640		○
2	Detection of Atrial Fibrillation in Patients Admitted with Ischaemic Stroke: A Non-systematic Review of the Asian Population. 2,		○
1	Clinical decision support to Optimize Care of patients with Atrial Fibrillation or flutter in the Emergency department: protocol of a stepped-wedge cluster randomized pragmatic trial (OCAF trial). 2023 , 24,		○